Several drugs have been studied, but none have demonstrated significant benefits, indicating a need for larger, well-designed, controlled trials
January 2024: The National Library of Medicine published a case report documenting gastroparesis development in a patient using semaglutide for weight reduction, though causation remained unestablished
Not for resale, diagnostic, or therapeutic applications
The Vaginal Health Conundrum Weight-loss drugs like Ozempic, originally designed for type 2 diabetes, are now being hailed for their ability to help with obesity
Metabolic Pharmaceuticals ultimately did not pursue Phase 3 trials for obesity, and the company's pipeline shifted toward other indications
Additionally, the long-term effects of melanocortin receptor stimulation are unknown, raising concerns about cardiovascular and other systemic effects